logo
Plus   Neg
Share
Email

Seattle Genetics To Receive $30 Mln Milestone Payment From Takeda - Quick Facts

Seattle Genetics, Inc. (SGEN) announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorization for ADCETRIS (brentuximab vedotin) to include ADCETRIS in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adults patients with previously untreated CD30+ stage IV classical Hodgkin lymphoma. Seattle Genetics will receive a milestone payment from Takeda of $30 million for the European Commission approval.

Clay Siegall, CEO at Seattle Genetics, said: "We look forward to continuing our work with Takeda to establish ADCETRIS as the global foundation of care for CD30-expressing lymphomas, including Hodgkin lymphoma."

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks recovered from an initial move to the downside but showed a lack of direction over the remainder of the trading session on Monday. The major averages spent most of the day bouncing back and forth across the unchanged line. Internet of Things platform EVRYTHNG is teaming up with IOTA Foundation to use IoT and distributed ledger technology to build a platform to provide transparency and provenance for consumer goods supply chains. EVRYTHNG is an IoT platform that activates every consumer product to make it intelligent, interactive and trackable, while IOTA is focused on DLT and permissionless ecosystem development. Target Corp. has introduced Everspring, a new household essentials brand comprised of more than 70 household essentials items that includes bio-based or recycled materials or natural fibers. The new, in-house brand has been designed by Target with sustainability in mind and is part of its efforts to make products that include ingredients derived from plants or renewable materials more accessible.
Follow RTT